We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VTX-801

News List

VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease drugs
August 20, 2021
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy.
Vivet, Pfizer sign manufacturing pact for investigational gene therapy to treat Wilson disease expresspharma
September 24, 2020
Vivet Therapeutics and Pfizer announced that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801 ...
Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics pharmafocusasia
March 21, 2019
Vivet Therapeutics, a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc.